Clinical Epidemiology and Ageing

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in -mutated non-small-cell lung cancer: a real life study.

Girard N, Moro-Sibilot D, Bouée S, Emery C, Torreton E, Le Lay K, Luciani L, Maritaz C, Chouaid C Future Oncol. 2020;16(16):1115-1124.

We aimed to assess the effectiveness and cost of patients with first line tyrosine kinase inhibitors (TKIs) sequence of first (1G) and second generation (2G) followed by osimertinib. Using the French nationwide claims and hospitalization database, we analyzed non-small-cell lung cancer patients who had been treated with osimertinib between April 2015 and December 2017, after a first line treatment with a TKI-1G/2G. The median time on treatment for sequential TKI-1G/2G followed by osimertinib was 34 months (95% CI: 31-46); 13 and 12months, respectively for TKI 1G or 2G and TKI 3G, respectively. The median overall survival for sequential TKI 1G or 2G followed by osimertinib was 37 months (95% CI: 34-42). The mean monthly costs per patient was €5162. These results, in line with those observed during clinical trials, confirm the effectiveness of the sequence TKI-1G/2G followed by osimertinib in -mutated non-small-cell lung cancer.

MeSH terms: Acrylamides; Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Health Care Costs; Humans; Insurance Claim Reporting; Lung Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; Survival Rate; Young Adult
DOI: 10.2217/fon-2020-0084